Last reviewed · How we verify
Adderall ® Immediate Release
Adderall is a combination of amphetamine salts that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system, enhancing focus and attention.
Adderall is a combination of amphetamine salts that increases the release and blocks the reuptake of dopamine and norepinephrine in the central nervous system, enhancing focus and attention. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.
At a glance
| Generic name | Adderall ® Immediate Release |
|---|---|
| Sponsor | NYU Langone Health |
| Drug class | Sympathomimetic amine; CNS stimulant |
| Target | Dopamine transporter (DAT); Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
The drug works by stimulating the release of catecholamines (dopamine and norepinephrine) from presynaptic neurons and inhibiting their reuptake, leading to increased synaptic concentrations. This mechanism enhances executive function, attention, and wakefulness. The immediate-release formulation provides rapid onset of action, typically within 30–60 minutes.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness or anxiety
- Tachycardia
- Elevated blood pressure
- Tremor
- Dry mouth
Key clinical trials
- A Within-Subject Cross-Over Comparison Between Immediate Release and Extended Release Adderall (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adderall ® Immediate Release CI brief — competitive landscape report
- Adderall ® Immediate Release updates RSS · CI watch RSS
- NYU Langone Health portfolio CI